Charalampos Papagoras1, Theodora E Markatseli1, Ioanna Saougou2, Yannis Alamanos3, Anastasia K Zikou4, Paraskevi V Voulgari1, Dimitrios N Kiortsis5, Alexandros A Drosos6. 1. Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece. 2. Pediatric Clinic, Medical School, University of Ioannina, 45110 Ioannina, Greece. 3. Department of Hygiene and Epidemiology, Medical School, University of Patras, 45110 Ioannina, Greece. 4. Department of Clinical Imaging, 45110 Ioannina, Greece. 5. Department of Pathophysiology, Medical School, University of Ioannina, 45110 Ioannina, Greece. 6. Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece. Electronic address: adrosos@cc.uoi.gr.
Abstract
OBJECTIVES: The spondyloarthritides (SpA) are associated with an increased cardiovascular risk. We studied cardiovascular risk factors in patients with SpA. METHODS: The following risk factors were assessed in SpA patients and healthy controls: smoking, family history of premature ischemic heart disease, obesity, serum lipids, apolipoproteins, urate and carotid intima media thickness (IMT). RESULTS: Overall 150 patients (73 with ankylosing spondylitis [AS], 71 with psoriatic arthritis [PsA] and six with other SpA types) were included. Generally SpA patients were significantly more often smokers, while PsA patients had greater values of abdominal obesity. AS patients had significantly lower levels of triglyceride, HDL, ApoB, ApoE and Lp(a) and a higher atherogenic index (total cholesterol/HDL). PsA patients had significantly lower levels of HDL, ApoAI and ApoE, an elevated atherogenic index and higher serum urate. In multivariate analysis the atherogenic index was positively associated with SpA across all patient groups independently of smoking and other lipid parameters. Carotid IMT in SpA patients (0.71 mm) was higher than controls (0.63 mm, P=0.017), although after adjusting for smoking this ceased to be significant. Treatment of patients with previously untreated disease resulted in a small but significant decline in ApoB levels at 6 months (P=0.045), which, however, was no longer evident at 12 months. CONCLUSION: Spondyloarthritis patients are at a greater cardiovascular risk owing to the higher prevalence of smoking and a higher atherogenic index. PsA patients have more abdominal fat and higher urate levels. Immunosuppressive treatment of SpA produces minor and temporary effects on the lipid profile.
OBJECTIVES: The spondyloarthritides (SpA) are associated with an increased cardiovascular risk. We studied cardiovascular risk factors in patients with SpA. METHODS: The following risk factors were assessed in SpA patients and healthy controls: smoking, family history of premature ischemic heart disease, obesity, serum lipids, apolipoproteins, urate and carotid intima media thickness (IMT). RESULTS: Overall 150 patients (73 with ankylosing spondylitis [AS], 71 with psoriatic arthritis [PsA] and six with other SpA types) were included. Generally SpA patients were significantly more often smokers, while PsA patients had greater values of abdominal obesity. AS patients had significantly lower levels of triglyceride, HDL, ApoB, ApoE and Lp(a) and a higher atherogenic index (total cholesterol/HDL). PsA patients had significantly lower levels of HDL, ApoAI and ApoE, an elevated atherogenic index and higher serum urate. In multivariate analysis the atherogenic index was positively associated with SpA across all patient groups independently of smoking and other lipid parameters. Carotid IMT in SpA patients (0.71 mm) was higher than controls (0.63 mm, P=0.017), although after adjusting for smoking this ceased to be significant. Treatment of patients with previously untreated disease resulted in a small but significant decline in ApoB levels at 6 months (P=0.045), which, however, was no longer evident at 12 months. CONCLUSION:Spondyloarthritispatients are at a greater cardiovascular risk owing to the higher prevalence of smoking and a higher atherogenic index. PsA patients have more abdominal fat and higher urate levels. Immunosuppressive treatment of SpA produces minor and temporary effects on the lipid profile.
Authors: F C Ernste; M Sánchez-Menéndez; K M Wilton; C S Crowson; E L Matteson; H Maradit Kremers Journal: Arthritis Care Res (Hoboken) Date: 2015-07 Impact factor: 4.794
Authors: Fernanda Genre; Javier Rueda-Gotor; Sara Remuzgo-Martínez; Alfonso Corrales; Verónica Mijares; Rosa Expósito; Cristina Mata; Virginia Portilla; Ricardo Blanco; José Luis Hernández; Javier Llorca; Oreste Gualillo; Raquel López-Mejías; Miguel A González-Gay Journal: Sci Rep Date: 2018-09-13 Impact factor: 4.379
Authors: Ana Maria Gherghe; Maxime Dougados; Bernard Combe; Robert Landewé; Carina Mihai; Francis Berenbaum; Xavier Mariette; Ron Wolterbeek; Désirée van der Heijde Journal: RMD Open Date: 2015-09-14